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302Background: The Mosaic porcine bioprosthesis (Medtronic, Inc, Minneapolis, Minn) was approved in 2000 by
the US Food and Drug Administration. Clinical performance was evaluated in 6 centers.
Methods: From 1994 to 2000, 797 patients (mean age 69 years) had aortic valve replacement (AVR) and 232
(mean 67 years) had mitral valve replacement (MVR). Concomitant coronary artery bypass grafting was per-
formed with aortic valve replacement (45.4%) and mitral valve replacement (43.5%). Mean follow-ups were
7.5 years for aortic position and 7.3 years for mitral position.
Results: Early mortalities were 2.8% for AVR and 3.0% for MVR. Late mortalities were 4.2%/patient-year for
AVR and 5.1%/patient-year for MVR. Overall 12-year survivals were 55.8%  3.7% for AVR and 43.9% 
7.4% forMVR. Twelve-year freedoms from valve-related mortality were 87.1% 3.1% for AVR and 82.5%
7.7% for MVR. Twelve-year freedoms from reoperation were 84.0% 3.3% for AVR and 82.5%  7.5% for
MVR. Freedoms from structural valve deterioration (SVD) by explant reoperation at 12 years for AVR were
93.3%  2.6% for patients at least 60 years old and 75.9%  9.3% for patients younger than 60 years. Free-
doms from SVD by explant reoperation at 10 years for MVR were 95.3%  7.8% for patients at least 70 years
old and 84.0%  9.3% for patients younger than 70 years. Hemodynamic performance data at 1 year for AVR
(sizes 21–27 mm) were mean systolic gradient range 13.7  4.8 to 10.3  3.2 mm Hg and effective orifice area
range 1.5 0.3 to 2.5 0.4 cm2. ForMVR (sizes 25–31 mm), data were mean diastolic gradient range 6.7 1.7
to 3.7  0.9 mm Hg and effective orifice area range 1.9  0.3 to 2.4  0.6 cm2.
Conclusions: Overall performance of Mosaic porcine bioprosthesis to 12 years is satisfactory. Freedoms from
SVD by explant reoperation were most satisfactory for aortic position in patients at least 60 years old and mitral
position in patients at least 70 years old. Overall actuarial freedom from SVD by explant reoperation is encour-
aging for patients with MVR. (J Thorac Cardiovasc Surg 2011;142:302-307)Supplemental material is available online.
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The Journal of Thoracic and Cardiovascular Surgintroduced advanced technology to address altered durabil-
ity of earlier bioprostheses. The Medtronic Mosaic has the
tissue fixed with glutaraldehyde while in a physiologic
state, incorporating predilatation of the aortic root, and
treated with the long-chain fatty acid a-amino oleic acid
to bind to the residual aldehyde moieties to mitigate calci-
fication.
The regulatory study commenced in 1994, with 17
primary centers participating in a prospective, nonrandom-
ized, multicenter trial in February 1994 in Europe and
September 1994 in Canada. The Medtronic Mosaic porcine
bioprosthesis was approved by the US FDA in 2000, which
was followed by a regulatory longitudinal study in the 6
participating centers that was closed July 14, 2002. The
evaluation of the prosthesis continued in the 6 original par-
ticipating centers, with a post–FDA longitudinal study
sponsor-initiated evaluation commencing August 19, 2004.
The reporting on the Medtronic Mosaic porcine biopros-
thesis has dealt with early to midterm clinical performance,
particularly related to thromboembolism and hemodynamic
performance.1-3 The purpose of this report is to document
the longitudinal experience of the 6 participating centers
with regard to reoperation for valve-related complications,ery c August 2011
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
FDA ¼ Food and Drug Administration
MVR ¼ mitral valve replacement
SVD ¼ structural valve deterioration
Jamieson et al Acquired Cardiovascular Diseaseas well as hemodynamic performance data from 1 partici-
pating center designated to perform this component of the
study.A
C
DMATERIALS AND METHODS
The total study population incorporated 1029 patients who received
Medtronic Mosaic porcine bioprostheses between 1994 and 2000. Institu-
tional ethical approval was achieved at each center, and informed consent
was obtained from the respective patients. The longitudinal evaluation was
conducted in 2 phases: the regulatory study which closed in July 2002, and
the industry-sponsored study that commencedAugust 2004. The initial reg-
ulatory study, with 6 centers participating, incorporated aortic valve re-
placement (AVR) in 797 patients (mean age 69 years, range 21–88
years) and mitral valve replacement (MVR) in 232 patients (mean age 67
years, range 17–84 years). In the AVR population, 710 patients were at least
60 years old and 87 were younger than 60 years, whereas in the MVR pop-
ulation, 126 were at least 70 years old and 106 were younger than 70 years.
Concomitant coronary artery bypass grafting was performed in 45.4% of
AVR recipients and 43.5% of MVR recipients.
At the completion of the regulatory longitudinal study in July 2002,
there were 702 AVR recipients and 202 MVR recipients alive. These pa-
tients were asked for new consent for the industry-sponsored phase, with
612 AVR recipients and 160 MVR recipients consenting.
Prospective echocardiographic evaluation was conducted in the partici-
pating center in Europe as part of the overall study protocol. This is re-
ported in the Results section.
Follow-up
The cumulative follow-ups were 6010.1 years for AVR and 1683.1 years
for MVR. The mean follow-up for AVR was 7.5  3.9 years (median 8.2
years), and that for MVR was 7.3  3.9 years (median 8.7 years). The
follow-up in each center was conducted by institutional procedures to eval-
uate reoperation for valve-related complications such as structural valve
deterioration (SVD). Serial echocardiograms were obtained at the Ham-
burg, Germany center. Follow-up was complete for 90.3% of AVR recip-
ients and 92.7% of MVR recipients. Study design requirement called for
regranting of consent at the end of the regulatory study phase. The closing
interval of follow-up was January 7, 2009. Of the 797 patients who under-
went AVR, 143 patients (17.9%) were not available for the industry-
sponsored study: 66 patients refused to continue in the study, 43 patients
could not be located, 10 patients moved to a different geographic area,
and 24 patients had other reasons for being unavailable for follow-up.
The percentage of patients unavailable for follow-up, excluding patients
who refused to continue in the study, was 9.7%. Of the 232 patients who
underwent MVR, 31 patients (13.4%) were unavailable for the industry-
sponsored study: 14 patients refused to continue in the study, 8 patients
could not be located, 3 patients moved to a different geographic area,
and 6 patients had other reasons for being unavailable for follow-up. The
percentage of patients unavailable for follow-up, excluding patients who
refused to continue in the study, was 7.3%.
The unavailability for follow-up rates of 9.7% for AVR and 7.3% for
MVR were contributed to by patients who dropped out of follow-up be-The Journal of Thoracic and Catween the 2 phases of the study. The major limitation of the study was
this lack of follow-up years between the 2 phases of the study; during
the interval, however, all 6 centers documented reoperations for SVD,
and these were included in the analysis. During the interval, there were
9 AVR SVD reoperations recorded but no MVR SVD reoperations.
Statistical Analysis
Patient survival was determined according to valve position by Kaplan–
Meier methodology. The definitions of valve-related complications—
thrombosis, SVD, nonstructural dysfunction (inclusive of periprosthetic
leak), periprosthetic leak, and valve-related reoperation—form part of
the documents on ‘‘Guidelines for ReportingMorbidity andMortality after
Cardiac Valvular Operations (Interventions).’’4,5 The early mortality data
(30 days) were reported as crude rates. The overall mortality data were
reported as linearized rates for the overall times, incorporating early and
late intervals.
The freedom from SVD demonstrated by reoperation, valve-related re-
operation, and valve-related mortality were determined by both actuarial
and actual or cumulative incidence methodologies. The analyses of age
groups (AVR60 and>60 years and MVR70 and>70 years) were con-
ducted on the basis of considered indications for bioprostheses. The free-
doms from SVD by reoperation were also analyzed by age groups
65 years and older and younger than 65 years for both AVR and MVR,
in accordance with the recommendations for prosthesis type by the Amer-
ican College of Cardiology and American Heart Association guidelines.6RESULTS
The early mortalities were 2.8% for AVR and 3.0% for
MVR. The overall mortalities were 4.2%/patient-year for
AVR and 5.1%/patient-year forMVR. The overall survivals
for the AVR population were 55.8% 3.7% at 12 years and
62.5%  2.3% at 10 years; those for MVR were 43.9% 
7.4% at 12 years and 58.6% 4.5% at 10 years (P¼ .12).
The survivals for patients undergoing AVR at 60 years and
older and at younger than 60 years are illustrated in Figure 1
(P ¼ .002). The survivals for patients undergoing MVR at
70 years and older and at younger than 70 years are illus-
trated in Figure 2 (P ¼ .11). The actuarial freedoms from
valve-related mortality at 12 years were 87.1%  3.1%
for AVR and 82.5%  7.7% for MVR (P ¼ .77).
The etiologic reasons for AVR andMVR reoperations are
detailed in Table 1. Thrombosis was the cause of 4 AVR and
2 MVR reoperations. There were 28 AVR reoperations for
SVD and 9 MVR reoperations for SVD.
Figures 3 through 6 illustrate the complete actuarial
analysis of SVD by explant reoperation, and Figures E1
and E2 illustrate actual (cumulative incidence) data. The
freedoms from SVD reoperation by actuarial analysis at
12 years were 91.0%  2.7% for AVR and 91.8% 
5.9% for MVR (P ¼ .53; Figure 3). The freedoms from
SVD reoperation by American College of Cardiology and
American Heart Association guidelines for age categories
65 years and older and younger than 65 years are summa-
rized in Table 2.
The actuarial freedoms for AVR reoperation for SVD by
age groups 60 years and older and younger than 60 years are
illustrated in Figure 4. The freedoms at 12 years wererdiovascular Surgery c Volume 142, Number 2 303
TABLE 1. Reoperation etiologies
Reason
Aortic valve
replacement
Mitral valve
replacement
Thrombosis 4 2
Endocarditis 20 3
Paravalvular leak 8 4
Nonstructural dysfunction 4 —
Structural valve deterioration 28 9
Incidental replacement 3 —
Total 67 18
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FIGURE 1. Survival for patients undergoing aortic valve replacement at
60 years and older and younger than 60 years.
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for younger than 60 years (P<.0001). The actuarial free-
doms for MVR reoperation for SVD by age groups 70 years
and older and younger than 70 years are shown in Figure 5.
The freedoms at 10 years were 95.3% 3.4% for 70 years
and older and 94.5%  3.9% for younger than 70 years
(P ¼ .47).
The actual (cumulative incidence) freedoms from AVR
and MVR reoperations for SVD stratified by age groups
are presented in Figures E1 and E2. The freedoms from
AVR reoperation for SVD at 12 years were 95.9% 
1.1% for 60 years and older and 80.6%  5.0% for
younger than 60 years. The freedoms from MVR
reoperation for SVD at 12 years were 96.7%  1.9% for
70 years and older and 90.3%  4.4% for younger than
70 years. The Weibull analysis for SVD in AVR andSURVIVAL MVR >=70 & <70 at 10yrs
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FIGURE 2. Survival for patients undergoing mitral valve replacement at
70 years and older and younger than 70 years.
304 The Journal of Thoracic and Cardiovascular SurgMVR groups (Figure 6) demonstrates similar performances
for AVR and MVR with regard to SVD.
The analysis of the cases of SVD consisted of echocar-
diographic, operative, pathologic, and radiologic findings.
For the 28 SVD cases in the AVR group, the average age
at implantation was 59.0 years and average duration since
implantation was 9.3 postoperative years. Leaflet tear was
the predominant lesion, with or without calcification. Perfo-
ration was identified in 4 cases of AVR. Stent dehiscence
was identified in 1 case of AVR. Pannus (1–3 mm of tissue
overgrowth) was incidentally observed in 14 cases of AVR.
Reported or healed endocarditis was considered in 2 AVR
cases, but the final diagnosis in both was SVD.
The average age of the 9 MVR recipients with SVD was
59.2 years, and the average duration since implantation was
9.1 postoperative years. For the 9 cases of SVD in the MVR
group, leaflet tear was predominant, with or without calcifi-
cation lesions. Perforation was identified in 1 case of MVR.
Pannus was also observed in 4 cases of MVR.
Radiographs were evaluated in 13 cases (11 AVR and
2 MVR). Commissural calcification was a significant find-
ing in 12 cases overall, at 1 to 3 commissures withFREEDOM FROM VALVE-RELATED (SVD) 
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FIGURE 3. Actuarial freedoms from reoperation for structural valve de-
terioration for aortic valve replacement (AVR) andmitral valve replacement
(MVR).
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FIGURE 4. Actuarial freedoms from reoperation for structural valve
deterioration for aortic valve replacement at 60 years and older and youn-
ger than 60 years.
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with commissural calcification identified also had evidence
of leaflet calcification on the radiologic evaluation.
Hemodynamic evaluations of AVR and MVR are graph-
ically illustrated in Figures E3 and E4. The aortic mean
systolic gradient for all valve sizes ranged from 12.5 
5.1 mm Hg at 1 year to 15.8  8.3 mm Hg at 10 years.
The effective aortic area ranged from 1.9  0.5 cm2 at 1
year to 1.7  0.4 cm2 at 10 years. The mitral mean
diastolic gradient for all valve sizes ranged from 4.9 
1.6 mg Hg at 1 year to 3.6  0.6 mm Hg at 10 years. The
effective mitral area ranged 2.0  0.5 cm2 at 1 year to 2.9
 0.7 cm2 at 10 years.DISCUSSION
The Medtronic Mosaic porcine bioprosthesis, which was
introduced in 1994with advanced technology for tissue pres-
ervation and calcium mitigation, is approaching time forFREEDOM FROM VALVE-RELATED (SVD) 
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FIGURE 5. Actuarial freedoms from reoperation for structural valve de-
terioration for mitral valve replacement at 70 years and older and younger
than 70 years.
The Journal of Thoracic and Caassessment of durability. There has been limited documenta-
tion addressing the durability of this bioprosthesis. The pub-
lications to date have evaluated thromboembolism and
thrombosis, as well as hemodynamic performance.1-3,7-10
In 2002, Eichenger and colleagues7 reporting on 561 pa-
tients from 5 European centers reported 1 case of SVD in
451 AVRs at a mean follow-up of 3.2 years. The second re-
port of SVD was by Botzenhardt and coauthors10 in 2004.
That case, identified at 4 years, incorporated 2 calcified im-
mobile leaflets.
The only report of the complete regulatory study popula-
tion was published in 2004 by Fradet and colleagues.2 The
1029 patients had a mean follow-up of 4.3 years and a max-
imum of 8 years. There was 100% freedom of SVD for both
aortic and mitral prostheses. The AVR recipients had
a mean age of 70 years, and the MVR recipients had
a mean age of 68 years.
In 2005, Jamieson and colleagues3 reported on the Van-
couver population of 657 patients. This patient cohort incor-
porated 188 patients contributed to the regulatory trial. This
report, at 6 years of evaluation, documented 4 cases of
SVD (2 aortic and 2 mitral). There was also 3 cases of pros-
theses thrombosis (2 aortic and 1 mitral) requiring reopera-
tion. The patients with SVD had 3 cases of leaflet tear
with mild to moderate calcification and 1 case of severe
calcific stenosis accompanying chronic renal failure and
hemodialysis.
Riess and colleagues8 in 2007 reported on the single Eu-
ropean center in the US FDA clinical trial. The mean
follow-ups were 6.1 years for aortic prostheses and 5.4
years for mitral prostheses. The maximum follow-up for
both was 10 years, and the mean age of both was 67 years.
The report documented 4 cases of aortic SVD reoperation
for regurgitation and stenosis. There were 4 cases of pros-
thesis thrombosis, 2 with congenital or acquired antithrom-
bin III deficiency. There were no cases of mitral SVD.
Riess and colleagues9 again reported on the Medtronic
Mosaic porcine bioprosthesis in 2009. They identified 9
cases of SVD among 255 AVR recipients and 1 case of
SVD among 47 MVR recipients. The mean age for both po-
sitions was 67 years. The 9 AVR cases involved aortic re-
gurgitation in 6 cases, 3 of these with combined aortic
stenosis, and 3 cases with isolated aortic stenosis. The sin-
gle MVR case involved stenosis. All of these patients came
to explant reoperation for the SVD. This center was the sin-
gle European center in our longitudinal study report. It was
also the only center that conducted prospective echocardi-
ography, but the report does not document SVD in nonoper-
ative cases.
The only other report on the post–FDA study cohort of
the 787 AVRs and 232 MVRs came in January 2007 in
a marketing document produced by Medtronic.11 This doc-
ument reported 17 AVR cases of SVD and 2 MVR cases of
SVD at explant reoperation from the 6 post–FDA approvalrdiovascular Surgery c Volume 142, Number 2 305
FIGURE 6. Structural valve deterioration (SVD) by Weibull analysis for aortic valve replacement (AVR) and mitral valve replacement (MVR).
TABLE 2. Actuarial freedom from reoperation for structural valve
deterioration for aortic valve replacement and mitral valve
replacement for patients 65 years old and older and patients younger
than 65 years
Patients at risk Freedom at 12 y
(%, mean ± SD)0 y 12 y
Aortic valve replacement
65 y 632 69 95.9%  2.3%*
<65 y 165 34 79.4%  6.2%
Mitral valve replacement
65 y 179 13 95.1%  2.9%y
<65 y 53 7 94.3%  5.2%
*P<.0001. yP ¼ .32.
Acquired Cardiovascular Disease Jamieson et al
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for AVR were 97.8%  3.9% for patients 65 years and
older and 84.4%  12.5% for patients younger than 65
years. The overall 10-year AVR freedom from SVD explant
was 94.0%  2.6%; the overall 10-year MVR freedom
from SVD explant was 97.1%  5.0%.
The Vancouver experience of 1172 patients (705 AVR
and 467 MVR) has again been documented (unpublished
data). The mean age for both positions was 71 years. The
mean follow-ups were 5.4 years for AVR and 4.5 years
for MVR. The evaluation, completed in early 2007, re-
vealed 7 cases of aortic SVD and 6 cases of mitral SVD
at reoperation or autopsy. The actuarial freedoms from
SVD at reoperation were 95.4% for AVR at 10 years and
97.6% for MVR at 8 years. There were an additional 14
AVR recipients and 2 MVR recipients with clinically diag-
nosed SVD, inclusive of echocardiographic examination.
The predominant operative finding was leaflet tear. Patho-
logic and radiologic examinations revealed commissural
calcification in a portion of the prostheses. There was also
documented commissural dehiscence.
This study is the second documentation of the post–FDA
study population. The mean follow-ups are now 7.5 years
for AVR and 7.3 years for MVR. The number of SVD cases
by explant reoperation has increased from 17 to 28 aortic
prostheses and from 2 to 9 mitral prostheses. The freedom
from SVD by reoperation is not differentiated by valve po-
sition. The predominant pathologic lesion has been leaflet
tear, with leaflet calcification not being a predominant le-
sion. Commissural calcification at 1 to 3 commissural re-
gions was also identified, but the study did not provide
the opportunity to address the potential overall incidence
of this finding in the general cohort population.306 The Journal of Thoracic and Cardiovascular SurgA limitation of the study is the lack of routine echocardi-
ography in all centers, to correlate with radiographic evalu-
ation of explanted prostheses to facilitate full evaluation of
failure modes. Only the European center participated in
prospective echocardiography as part of the study protocol.
A further limitation of the study is the interval between the
completion of the regulatory longitudinal study and the
commencement of the sponsor-stimulated longitudinal
study. This interval is reflected in the completeness of
follow-up and the factors contributing to the extent of
follow-up. The patients were subjected to a new consent
process for the sponsor-stimulated longitudinal study,
which resulted in reduction in the completeness of follow-
up. Regardless of this limitation, cases of SVD that oc-
curred in the interval were reported by each of the 6 partici-
pating centers and were included in the statistical analysis,
probably lowering the freedom from SVD in the aortic po-
sition because of the lack of supporting follow-up during
this interval.ery c August 2011
Jamieson et al Acquired Cardiovascular DiseaseThe study has revealed the most satisfactory freedoms
from SVD diagnosed by explant reoperation for AVR in pa-
tients 60 years and older and for MVR in patients 70 years
and older. The prosthesis rate of failure appears to be similar
between aortic and mitral positions. The durability is partic-
ularly satisfactory forMVR. TheMedtronicMosaic porcine
bioprosthesis needs continued evaluation and comparison
with other bioprostheses that are approaching 20 years of
follow-up.A
C
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FIGURE E1. Actual freedoms (cumulative incidence) from reoperation
for structural valve deterioration for aortic valve replacement at 60 years
and older and younger than 60 years.
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FIGURE E2. Actual freedom (cumulative incidence) from reoperation
for structural valve deterioration for mitral valve replacement at 70 years
and older and younger than 70 years.
FIGURE E3. Hemodynamics for aortic valve replacement. A, Mean sys-
tolic gradient in millimeters of mercury. B, Effective orifice area in square
centimeters.
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FIGURE E4. Hemodynamics for mitral valve replacement. A, Mean sys-
tolic gradient in millimeters of mercury. B, Effective orifice area in square
centimeters.
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